Identification of genetic and immune signatures for the recurrence of HER2-positive breast cancer after trastuzumab-based treatment

Xu, Chi; Wang, Yahui; Hong, Yuanyuan; Yao, Ru; Wu, Lijia; Shen, Xi; Qu, Yang; Zhang, Zhuo; Zhu, Wei; Yang, Ying; Chen, Weizhi; Zhou, Yidong; Zeng, Liang

doi:10.1007/s10549-023-06931-1

Breast Cancer Res Treat

2023

DOI: 10.1007/s10549-023-06931-1

|View full text |Cite

Identification of genetic and immune signatures for the recurrence of HER2-positive breast cancer after trastuzumab-based treatment

Chi Xu

Yahui Wang

Yuanyuan Hong

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Resistance mechanisms and prospects of trastuzumab

Wang,

et al. 2024

Front. Oncol.

View full text Add to dashboard Cite

Breast cancer that overexpresses Human Epidermal Growth Factor Receptor 2 (HER2+) due to gene amplification or overexpression constitutes 15-20% of all breast cancer cases. Trastuzumab, the first FDA-approved monoclonal antibody targeting HER2, serves as the standard first-line treatment for HER2-positive advanced breast cancer, as recommended by multiple clinical guidelines.Currently, accumulated clinical evidence reveals a considerable degree of variability in the response of HER2+ breast cancer to trastuzumab treatment. Specifically, over 50% of patients either do not respond to or develop resistance against trastuzumab.The specific mechanisms of resistance to trastuzumab are currently unclear. This paper aims to review the existing research on the resistance mechanisms of trastuzumab, based on its target, from aspects such as genetic loci, molecular structure, signaling pathways, and the tumor microenvironment and to outline current research progress and new strategies.

show abstract

Resistance mechanisms and prospects of trastuzumab

Wang,

et al. 2024

Front. Oncol.

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Identification of genetic and immune signatures for the recurrence of HER2-positive breast cancer after trastuzumab-based treatment

Cited by 1 publication

References 53 publications

Resistance mechanisms and prospects of trastuzumab

Resistance mechanisms and prospects of trastuzumab

Contact Info

Product

Resources

About